StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
INCYINCYTE CORP
stockpulse.co.kr
Nasdaq
$115.00▼ 0.62%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $22.97BShares out 200M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

27
  • 5d agoAfter-hours26.10.20 05:38
    4Ownership#●●●

    INCYTE CORP

    Incyte Corp insider Pablo J. Cagnoni reported a change in beneficial ownership of securities effective October 15, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more

    $115.00-0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.15After-hours26.10.16 05:01
    144Ownership

    INCYTE CORP

    Pablo J. Cagnoni, an insider at Incyte Corp, has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard regulatory filing disclosing an insider's plan to dispose of their holdings.…more

    $115.00-0.62%vs prev close
    View filingShare
  • 10.5After-hours26.10.06 05:01
    4Ownership

    INCYTE CORP

    Incyte Corp insider Heeson Lee filed a Form 4 report on October 5, 2026, regarding changes in beneficial ownership of securities as of October 1, 2026. This filing serves as an official disclosure of insider stock activity to the SEC.…more

    $115.00-0.62%vs prev close
    View filingShare

26 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.28Regular26.09.29 01:54
    Bullish#●●●#●●●#●●●

    FDA Expands Approval of Eli Lilly's Olumiant for Adolescent Alopecia Areata…more

    The FDA has expanded the approval of Eli Lilly's Olumiant to include adolescents aged 12 and older suffering from severe alopecia areata. This decision follows positive Phase 3 clinical trial results demonstrating significant scalp hair regrowth in pediatric patients.…more

    $115.00-0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.28Pre-market26.09.28 21:38

    ●●●●●●●● ●●●●● ●●●●●●

    Mirum Pharmaceuticals and Incyte have received FDA approval for Atebrioz, a once-daily oral treatment for fibrodysplasia ossificans progressiva. The drug demonstrated clinical efficacy by significantly reducing the volume of abnormal bone formation in patients.…more

    $115.00-0.62%vs prev close
    ShareBenzinga
  • 9.25Regular26.09.26 03:53

    ●●●●●●●● ●●●●● ●●●●●●

    The FDA has approved Atebrioz for the treatment of adults and pediatric patients aged 12 and older with Fibrodysplasia Ossificans Progressiva. This regulatory approval provides a new therapeutic option and strengthens the company's market position.…more

    $115.00-0.62%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →